Dario Gutierrez, PhD


Dr. Gutierrez joined TCR² in 2019 as Vice President of Discovery and Innovation. Dario has more than a decade of experience focusing on innovative immunology and drug discovery, including allogeneic and gamma-delta T cell therapies. Previously, he was Director and Head of Investigational Biology and Immuno-Biology in the Merck Exploratory Science Center at Merck & Co., where he was responsible for establishing discovery programs consisting of different modalities such as small molecules, biologics and cell therapy, and a diverse portfolio that includes reverse-translational systems immunology discovery and multiple immuno-oncology target identification efforts. Prior to joining Merck, Dario worked at Evelo Biosciences as a Senior Scientist and Head of Immune Tolerance. Before joining the biotechnology industry, Dario worked as a postdoctoral scientist in the Division of Cellular Immunology at the German Cancer Research Center. Dr. Gutierrez received his PhD in Molecular Physiology and Biophysics from Vanderbilt University and BS in Biochemistry from California State University, San Bernardino.